459 related articles for article (PubMed ID: 27264969)
1. The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells.
Wang X; Mazurkiewicz M; Hillert EK; Olofsson MH; Pierrou S; Hillertz P; Gullbo J; Selvaraju K; Paulus A; Akhtar S; Bossler F; Khan AC; Linder S; D'Arcy P
Sci Rep; 2016 Jun; 6():26979. PubMed ID: 27264969
[TBL] [Abstract][Full Text] [Related]
2. Sensitivity of Acute Myelocytic Leukemia Cells to the Dienone Compound VLX1570 Is Associated with Inhibition of the Ubiquitin-Proteasome System.
Selvaraju K; Lotfi K; Gubat J; Miquel M; Nilsson A; Hill J; Jensen LD; Linder S; D'Arcy P
Biomolecules; 2021 Sep; 11(9):. PubMed ID: 34572552
[TBL] [Abstract][Full Text] [Related]
3. Acute lymphoblastic leukemia cells are sensitive to disturbances in protein homeostasis induced by proteasome deubiquitinase inhibition.
Mazurkiewicz M; Hillert EK; Wang X; Pellegrini P; Olofsson MH; Selvaraju K; D'Arcy P; Linder S
Oncotarget; 2017 Mar; 8(13):21115-21127. PubMed ID: 28423502
[TBL] [Abstract][Full Text] [Related]
4. Analysis of determinants for in vitro resistance to the small molecule deubiquitinase inhibitor b-AP15.
Mofers A; Perego P; Selvaraju K; Gatti L; Gullbo J; Linder S; D'Arcy P
PLoS One; 2019; 14(10):e0223807. PubMed ID: 31639138
[TBL] [Abstract][Full Text] [Related]
5. Induction of ER Stress in Acute Lymphoblastic Leukemia Cells by the Deubiquitinase Inhibitor VLX1570.
Pellegrini P; Selvaraju K; Faustini E; Mofers A; Zhang X; Ternerot J; Schubert A; Linder S; D Arcy P
Int J Mol Sci; 2020 Jul; 21(13):. PubMed ID: 32635430
[TBL] [Abstract][Full Text] [Related]
6. Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells.
Paulus A; Akhtar S; Caulfield TR; Samuel K; Yousaf H; Bashir Y; Paulus SM; Tran D; Hudec R; Cogen D; Jiang J; Edenfield B; Novak A; Ansell SM; Witzig T; Martin P; Coleman M; Roy V; Ailawadhi S; Chitta K; Linder S; Chanan-Khan A
Blood Cancer J; 2016 Nov; 6(11):e492. PubMed ID: 27813535
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and evaluation of derivatives of the proteasome deubiquitinase inhibitor b-AP15.
Wang X; D'Arcy P; Caulfield TR; Paulus A; Chitta K; Mohanty C; Gullbo J; Chanan-Khan A; Linder S
Chem Biol Drug Des; 2015 Nov; 86(5):1036-48. PubMed ID: 25854145
[TBL] [Abstract][Full Text] [Related]
8. Cadmium pyrithione suppresses tumor growth in vitro and in vivo through inhibition of proteasomal deubiquitinase.
Chen X; Wu J; Yang Q; Zhang X; Zhang P; Liao S; He Z; Wang X; Zhao C; Liu J
Biometals; 2018 Feb; 31(1):29-43. PubMed ID: 29098502
[TBL] [Abstract][Full Text] [Related]
9. VLX1570 induces apoptosis through the generation of ROS and induction of ER stress on leukemia cell lines.
Kurozumi N; Tsujioka T; Ouchida M; Sakakibara K; Nakahara T; Suemori SI; Takeuchi M; Kitanaka A; Shibakura M; Tohyama K
Cancer Sci; 2021 Aug; 112(8):3302-3313. PubMed ID: 34032336
[TBL] [Abstract][Full Text] [Related]
10. Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma.
Rowinsky EK; Paner A; Berdeja JG; Paba-Prada C; Venugopal P; Porkka K; Gullbo J; Linder S; Loskog A; Richardson PG; Landgren O
Invest New Drugs; 2020 Oct; 38(5):1448-1453. PubMed ID: 32125598
[TBL] [Abstract][Full Text] [Related]
11. Targeted inhibition of the deubiquitinating enzymes, USP14 and UCHL5, induces proteotoxic stress and apoptosis in Waldenström macroglobulinaemia tumour cells.
Chitta K; Paulus A; Akhtar S; Blake MK; Caulfield TR; Novak AJ; Ansell SM; Advani P; Ailawadhi S; Sher T; Linder S; Chanan-Khan A
Br J Haematol; 2015 May; 169(3):377-90. PubMed ID: 25691154
[TBL] [Abstract][Full Text] [Related]
12. A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance.
Tian Z; D'Arcy P; Wang X; Ray A; Tai YT; Hu Y; Carrasco RD; Richardson P; Linder S; Chauhan D; Anderson KC
Blood; 2014 Jan; 123(5):706-16. PubMed ID: 24319254
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of proteasome deubiquitinating activity as a new cancer therapy.
D'Arcy P; Brnjic S; Olofsson MH; Fryknäs M; Lindsten K; De Cesare M; Perego P; Sadeghi B; Hassan M; Larsson R; Linder S
Nat Med; 2011 Nov; 17(12):1636-40. PubMed ID: 22057347
[TBL] [Abstract][Full Text] [Related]
14. Repurposing an antidandruff agent to treating cancer: zinc pyrithione inhibits tumor growth via targeting proteasome-associated deubiquitinases.
Zhao C; Chen X; Yang C; Zang D; Lan X; Liao S; Zhang P; Wu J; Li X; Liu N; Liao Y; Huang H; Shi X; Jiang L; Liu X; Dou QP; Wang X; Liu J
Oncotarget; 2017 Feb; 8(8):13942-13956. PubMed ID: 28086217
[TBL] [Abstract][Full Text] [Related]
15. A novel nickel complex works as a proteasomal deubiquitinase inhibitor for cancer therapy.
Zhao C; Chen X; Zang D; Lan X; Liao S; Yang C; Zhang P; Wu J; Li X; Liu N; Liao Y; Huang H; Shi X; Jiang L; Liu X; He Z; Dou QP; Wang X; Liu J
Oncogene; 2016 Nov; 35(45):5916-5927. PubMed ID: 27086925
[TBL] [Abstract][Full Text] [Related]
16. USP14 is a predictor of recurrence in endometrial cancer and a molecular target for endometrial cancer treatment.
Vogel RI; Pulver T; Heilmann W; Mooneyham A; Mullany S; Zhao X; Shahi M; Richter J; Klein M; Chen L; Ding R; Konecny G; Kommoss S; Winterhoff B; Ghebre R; Bazzaro M
Oncotarget; 2016 May; 7(21):30962-76. PubMed ID: 27121063
[TBL] [Abstract][Full Text] [Related]
17. Targeting the Proteasome-Associated Deubiquitinating Enzyme USP14 Impairs Melanoma Cell Survival and Overcomes Resistance to MAPK-Targeting Therapies.
Didier R; Mallavialle A; Ben Jouira R; Domdom MA; Tichet M; Auberger P; Luciano F; Ohanna M; Tartare-Deckert S; Deckert M
Mol Cancer Ther; 2018 Jul; 17(7):1416-1429. PubMed ID: 29703842
[TBL] [Abstract][Full Text] [Related]
18. Blockade of deubiquitylating enzyme Rpn11 triggers apoptosis in multiple myeloma cells and overcomes bortezomib resistance.
Song Y; Li S; Ray A; Das DS; Qi J; Samur MK; Tai YT; Munshi N; Carrasco RD; Chauhan D; Anderson KC
Oncogene; 2017 Oct; 36(40):5631-5638. PubMed ID: 28581522
[TBL] [Abstract][Full Text] [Related]
19. Proteasome inhibition correlates with intracellular bortezomib concentrations but not with antiproliferative effects after bolus treatment in myeloma cell lines.
Dettmer S; Theile D; Schäfer J; Seckinger A; Burhenne J; Weiss J
Naunyn Schmiedebergs Arch Pharmacol; 2016 Oct; 389(10):1091-101. PubMed ID: 27422413
[TBL] [Abstract][Full Text] [Related]
20. Structure-function analyses of candidate small molecule RPN13 inhibitors with antitumor properties.
Anchoori RK; Tan M; Tseng SH; Peng S; Soong RS; Algethami A; Foran P; Das S; Wang C; Wang TL; Liang H; Hung CF; Roden RBS
PLoS One; 2020; 15(1):e0227727. PubMed ID: 31940398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
